Idiopathic Pulmonary Fibrosis clinical trials at UCSD
3 in progress, 1 open to eligible people
TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
open to eligible people ages 40 years and up
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
La Jolla, California and other locations
Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Sorry, not currently recruiting here
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
San Diego, California and other locations
Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sorry, in progress, not accepting new patients
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
La Jolla, California and other locations
Last updated: